Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Mark H N Corrigan - aVenture Research

Mark H N Corrigan

AddedFeb 14, 2024

UpdatedOct 16, 2026

Mark H N Corrigan

Mark H N Corrigan

CEO, Tremeau Pharmaceuticals

Mark H N Corrigan's Career

Epirus Biopharmaceuticals

Public

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

$83.1M

Boston, MA, US

Board Member· Board

Wave Life Sciences

Public$324MCambridge, MA, US

Board Member· Board

Trevena

Public$473.7MKing of Prussia, PA, US

Board Member· Board

Pamlico Biopharma

Series A$2.2MOklahoma City, OK, US

Board Member· Board

Synereca Pharmaceuticals

Pre-Seed$2.3MChapel Hill, NC, US

Board Member· Board

Quartet Medicine

Series A$23MCambridge, MA, US

Board Member· Board

BlackThorn Therapeutics

$138MSan Francisco, CA, US

Board Member· Board

Tremeau Pharmaceuticals

Late Stage Private$115.2MConcord, MA, US

Board Member· Board

CEO· C-Suite · Management

Co-Founder

People Similar to Mark H N Corrigan

Matthew K FustBoard Member · BlackThorn Therapeutics

Bill MartinCEO · BlackThorn Therapeutics

Dr Thomas R Beck "Tom"Board Member · NeuroTherapeutics Pharma

Xiaoming ZhangCo-Founder · Theron Pharmaceuticals

Terry GouldBoard Member · Outpost Medicine

Wendye RobbinsCo-Founder · NeurogesX

Similar to Epirus Biopharmaceuticals

NeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30

Osprey Pharmaceuticals USASan Francisco, CA, USTherapeuticsest. 1998Osprey Pharmaceuticals USASan Francisco, CA, US · est. 1998

Osprey Pharmaceuticals USA: Innovating protein therapeutics for inflammatory and immune diseases.

Series A · $29.7M30

ComplexaPittsburgh, PA, USTherapeuticsest. 2008ComplexaPittsburgh, PA, US · est. 2008

Complexa, Inc.: A biopharmaceutical firm innovating therapies for inflammatory and metabolic diseases.

Public · $86.9M7

Epirium BioSan Diego, CA, USTherapeuticsest. 2008Epirium BioSan Diego, CA, US · est. 2008

San Diego-based medical organization, Epirium Bio Inc, specializes in innovative medical research.

Series A · $86.4M30

Leadership at Wave Life Sciences

Christian HenryBoard Member

Gregory L. VerdineCo-Founder

Takeshi WadaCo-Founder

Ken TakanashiBoard Member

Adrian RawcliffeBoard Member

Similar to Wave Life Sciences

Ionis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796

Leadership at Trevena

Robert LefkowitzCo-Founder

Howard RockmanBoard Member

Scott BraunsteinBoard Member

Lonnie MoulderBoard Member

Carrie L. BourdowBoard Member

Barbara YanniBoard Member

Similar to Trevena

BiohavenNew Haven, CT, USPharmaceuticalsest. 2013BiohavenNew Haven, CT, US · est. 2013

Biohaven: A clinical-stage biopharmaceutical firm targeting neurological diseases with innovative treatments.

Tris PharmaMonmouth Junction, NJ, US

Leadership at Pamlico Biopharma

Clayton I. DuncanBoard Member

Similar to Pamlico Biopharma

IdbiologicsNashville, TN, USAntibodies, Therapeuticsest. 2017IdbiologicsNashville, TN, US · est. 2017

IDBiologics: Pioneering infectious disease treatment through rapid discovery and optimization of human monoclonal antibodies.

BioClonetics ImmunotherapeuticsRockwall, TX, USAntibodies, Biopharmaceuticalsest. 2009BioClonetics ImmunotherapeuticsRockwall, TX, US · est. 2009

BioClonetics: A biotech firm developing and producing monoclonal antibodies to combat infectious diseases.

Public · $255.6k6

MicrobplexAtlanta, GA, USDiagnostic Platformsest. 2011MicrobplexAtlanta, GA, US · est. 2011

MicroBPlex develops diagnostic platforms using innovative antibodies to identify acute microbial infections.

DxDiscoveryReno, NV, USDiagnostics, Therapeuticsest. 2012DxDiscoveryReno, NV, US · est. 2012

DxDiscovery: A Reno-based biotech firm specializing in developing microbial monoclonal antibodies for disease prevention, treatment, and rapid diagnostics.

Leadership at Synereca Pharmaceuticals

Bennett LoveFounder

Similar to Synereca Pharmaceuticals

Recreo PharmaceuticalsSuperior, CO, USAntibody Therapeuticsest. 2013Recreo PharmaceuticalsSuperior, CO, US · est. 2013

Recreo Pharmaceuticals: Innovating antibody therapeutics to combat antibiotic resistance.

Recida TherapeuticsMenlo Park, CA, USPharmaceuticalsest. 2016Recida TherapeuticsMenlo Park, CA, US · est. 2016

Recida Therapeutics, Inc.: A biopharmaceutical firm developing treatments for antibiotic-resistant infections.

Series A · $18.6M5

Cardeas PharmaSeattle, WA, USAntibiotics, Pharmaceuticalsest. 2010Cardeas PharmaSeattle, WA, US · est. 2010

Cardeas Pharma: Specializing in developing inhaled antibiotics for respiratory infections.

Series B · $80M30

Viosera TherapeuticsSt. Louis, MO, USDrug Discoveryest. 2016Viosera TherapeuticsSt. Louis, MO, US · est. 2016

Viosera Therapeutics: Innovating drug combinations to combat resistance in cancer and bacterial infections.

Leadership at Quartet Medicine

Gerhard KoenigBoard Member

Bruce BoothBoard Member

Henry B. SkinnerBoard Member

John CreecyBoard Member

Kevin PojasekFounder

Similar to Quartet Medicine

Tremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Late Stage Private · $115.2M11

Leadership at BlackThorn Therapeutics

George GolumbeskiBoard Member

Alex TkachenkoFounder

Kristina BurowBoard Member

Paul L. BernsBoard Member

Julie SunderlandBoard Member

Lori HuBoard Member

Similar to BlackThorn Therapeutics

Mahzi TherapeuticsSan Mateo, CA, USBiotechest. 2020Mahzi TherapeuticsSan Mateo, CA, US · est. 2020

Mahzi Therapeutics: A California-based healthcare and biotech firm, founded in 2020.

Series A · $47.3M13

Leadership at Tremeau Pharmaceuticals

Brad SippyBoard Member

Similar to Tremeau Pharmaceuticals

TrigeminaMoraga, CA, USPain Treatmentsest. 2006TrigeminaMoraga, CA, US · est. 2006

Trigemina, Inc.: A US-based pharmaceutical company innovating non-opiate pain therapies.

Series A · $27.6M11

Solace PharmaceuticalsCambridge, MA, USPain Reliefest. 2006Solace PharmaceuticalsCambridge, MA, US · est. 2006

Solace Pharmaceuticals: Boston-based provider of therapeutic solutions for chronic pain.

Public · $15M5

Centrexion TherapeuticsBoston, MA, USPain Therapiesest. 2013Centrexion TherapeuticsBoston, MA, US · est. 2013

US-based Centrexion Therapeutics develops non-opioid, non-addictive therapies for chronic pain treatment.

Public · $229.2M22

Quartet MedicineCambridge, MA, USPain Medicationsest. 2013Quartet MedicineCambridge, MA, US · est. 2013

Quartet Medicine: Innovating novel treatments for chronic pain and inflammation.

Series A · $23M7

Korro BioCambridge, MA, USRNA Editing, Treatmentsest. 2018

Korro BioCambridge, MA, US · est. 2018

Korro Bio: Innovating extraordinary treatments for patient care.

Public · $207.5M99

Ochre BioOxford, Oxfordshire, GBRNA Medicinesest. 2019Ochre BioOxford, Oxfordshire, GB · est. 2019

Ochre Bio: Biotech firm creating RNA meds & platforms for liver health.

Series A · $39.8M56

InceptivePalo Alto, CA, USMedicines, RNA Designest. 2021InceptivePalo Alto, CA, US · est. 2021

RNA design firm using deep learning and high-throughput experiments to create innovative medicines and biotechnologies.

Series A · $120M29

Pharmaceuticalsest. 2000

Tris PharmaMonmouth Junction, NJ, US · est. 2000

Tris Pharma, a New Jersey-based medical organization, innovates drug delivery technologies and medicines for disease treatment.

Public · $141.6M350

Acadia PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 1993Acadia PharmaceuticalsSan Diego, CA, US · est. 1993

ACADIA Pharmaceuticals: A San Diego-based biopharmaceutical company specializing in CNS disorder treatments.

Tremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Late Stage Private · $115.2M11

Solace PharmaceuticalsCambridge, MA, USPain Reliefest. 2006

Solace PharmaceuticalsCambridge, MA, US · est. 2006

Solace Pharmaceuticals: Boston-based provider of therapeutic solutions for chronic pain.

Public · $15M5

Centrexion TherapeuticsBoston, MA, USPain Therapiesest. 2013Centrexion TherapeuticsBoston, MA, US · est. 2013

US-based Centrexion Therapeutics develops non-opioid, non-addictive therapies for chronic pain treatment.

Public · $229.2M22

TrigeminaMoraga, CA, USPain Treatmentsest. 2006TrigeminaMoraga, CA, US · est. 2006

Trigemina, Inc.: A US-based pharmaceutical company innovating non-opiate pain therapies.

Series A · $27.6M11

Chase TherapeuticsWashington, D.C., DC, USPharmaceuticalsest. 2017

Chase TherapeuticsWashington, D.C., DC, US · est. 2017

Chase Therapeutics: An early-stage pharmaceutical company innovating superior brain disease treatments.

Series B · $25.3M175

NeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30

Orphan Star TherapeuticsNew York City, NY, USTherapiesest. 2017Orphan Star TherapeuticsNew York City, NY, US · est. 2017

Orphan Star Therapeutics: A NY-based biopharmaceutical firm developing therapies for rare diseases.

Series B · $20M5